Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA Deferred Revenue (Non-current)
Payments received for goods or services the company will deliver after more than one year.
Zura Bio LimitedNASDAQ: ZURA
Deferred Revenue (Non-current) · Q1 FY2026 · quarter ended Mar 2026
Deferred revenue (non-current) remains negative
Q1 FY2026 deferred revenue (non-current) was $0, compared with $0 a year earlier.
Context
- Deferred revenue (non-current) amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Deferred revenue (non-current) increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue (Non-current) history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Deferred Revenue (Non-current) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2022-03-31 | 0 | — |
Deferred Revenue (Non-current) vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's Mar 2026 deferred revenue (non-current) of $0 is the 3rd highest of the 11 companies compared; the peer median is $0.
- Deferred revenue (non-current) amounts to 0.0% of total assets for ZURA, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $193.59M | -13.0% | -12.2% | 87.1% | |
| Mar 2026 | $4.68M | — | — | 3.5% | |
ZURAZura Bio Limited | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ZURA) | $0 | -56.5% | -12.2% | 0.0% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.